BMY - Bolt Biotherapeutics sheds half its value following mid-stage solid tumor data

Bolt Biotherapeutics (BOLT -50.7%) has lost its charge today following the release of interim results of phase 1/2 data on BDC-1001 for solid tumors. Early signs of clinical activity were seen in 13 of 40 tumor evaluable subjects. One durable partial response was maintained through one year. Bolt said that the data points "to the need for increased drug exposure to optimize clinical benefit." The company added that a dose-escalation study of BDC-1001 in combination with Opdivo (nivolumab) is slated to start by the end of the year. That study is part of a clinical collaboration with Bristol-Myers Squibb (BMY +1.4%).

For further details see:

Bolt Biotherapeutics sheds half its value following mid-stage solid tumor data